Bio
CEO
Pilar Ferrer
Biologist and PhD student in Cardiac Regenerative Medicine at IMETTYB (Favaloro University – CONICET), based in Buenos Aires, Argentina.
CEO and Co-Founder of Amnova Biotech, developing biomimetic injectable therapies for heart regeneration after ischemic injury.
Currently part of the START Fellowship (University of St. Gallen, Switzerland), where she is expanding the company internationally, leading fundraising, regulatory strategy, and partnerships to bring cardiac regeneration from the laboratory to clinical practice.
Bio
CTO
Mariano Berra
Pharmacist graduated from the University of Morón, with extensive experience in technical management, quality assurance, regulatory affairs, process development, and analytical validation.
Co-Founder and CTO of AMNOVA Biotech.
Founder and Director of non-governmental organization tissue bank AMNIOSBMA leading the quality management system, regulatory affair and the development of birth tissue–derived products in compliance with Good Manufacturing Practices (GMP). I participate in basic, applied, and translational research projects in regenerative medicine, particularly in wound care and ophthalmology.
Merck Group | Co-Technical Director & Head of Quality Control, Analytical Development Spearheaded the integrated management of Quality Control and Analytical Development during the company’s strategic transition, which prioritized the biotechnology pipeline. Directly responsible for the oversight of Microbiology, Quality Control, and Stability laboratories for recombinant DNA (r-DNA) technology products. Played a pivotal role as the regulatory interface with ANMAT, successfully navigating the inspections required for the launch of new formulations and high-complexity critical products. This leadership ensured the quality and regulatory compliance of market-leading therapies such as Gonal-f®, Ovitrelle®, Saizen®, Rebif®, and monoclonal antibodies like Erbitux®.
Extensive management experience in the public healthcare sector, comprising hospitals and institutions under the Ministry of Health of the Province of Buenos Aires. Key areas of focus include primary healthcare and pharmaceutical policy
Bio
CSO
Daniela Olea
Biotechnologist from the National University of Quilmes and holds a PhD in Basic Medical Sciences from the University of Buenos Aires. Independent Researcher at the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), based at IMETTyB (Favaloro University–CONICET), and Full Professor at the Faculty of Medical Sciences, Favaloro University.
With over 20 years of experience in cardiovascular regenerative medicine, she has led translational research programs focused on myocardial infarction and peripheral arterial disease, developing advanced therapeutic strategies including protein-, gene-, cell-, and biomaterial-based approaches. Her work bridges preclinical validation and clinically relevant applications.
Dr. Olea is the author of more than 25 peer-reviewed publications in high-impact journals and recipient of 14 competitive research awards and grants. She has extensive experience leading multidisciplinary teams, supervising doctoral and postdoctoral fellows, and managing complex experimental and translational projects.
As Scientific Founder of AMNOVA, she leads the strategic development of regenerative therapies derived from amniotic biomaterials, guiding scientific design, preclinical validation, intellectual property strategy, and translational roadmap toward clinical application.
Bio
Scientific Advisor
Alejandro Berra
Biochemist and PhD, Faculty of Pharmacy and Biochemistry, University of Buenos Aires with + 35 years of experience in Translational research, biomedical R&D.
Board member non-governmental organization tissue bank AMNIOSBMA
Major interests: Tissue Regeneration in Ophthalmology, wound healing, heart failure.
Accomplishments, Principal Researcher´s Argentine National Council for Scientific and Technical Research, 2 Research Fellowships in Basic Research and Ocular Immunology, Harvard Medical School, + 5 Patents, +40 Publications, +200 Lectures.